A 12-week treatment for eosinophilic esophagitis (EoE) in patients 11 years of age and older. EOHILIA has not been shown to be safe and effective for longer than 12 weeks.1

Illustration of esophageal inflammation

FIRST AND ONLY FDA-APPROVED oral treatment for EoE for 12-week use in patients 11 years and older. EOHILIA has not been shown to be safe and effective for longer than 12 weeks.1


DESIGNED FOR EoE.

Inflammation relief where it matters.

EOHILIA is a portable, oral budesonide suspension designed specifically for EoE. Relief was defined as reduction in eosinophils in the esophagus and improvement in dysphagia symptoms in two 12-week clinical trials.1

Clinical program background image
The efficacy and safety profile of EOHILIA was evaluated in one of the

LARGEST CLINICAL PROGRAMS

of patients with EoE in the U.S.1

Histological remission and dysphagia symptom responses with EOHILIA were studied in two 12-week clinical trials that included 410 patients 11-56 years of age with EoE.1

The safety profile of EOHILIA was evaluated in 410 patients with EoE in two 12-week clinical trials.1

Explore a

BROAD RANGE

of patient types

Take a closer look at different patient types and see if they are similar to your patients with EoE.

Image of EOHILIA™ (budesonide oral suspension) box and stick pack

PORTABLE FOR ON THE GO

Consistent formulation is premixed in single-dose stick packs for reliable budesonide dosing.1

Resources background image

RESOURCES

at your fingertips

Help your patients navigate their treatment journey at every step. Get resources designed to inform and support.

Images of downloadable & printable resources for EOHILIA™ (budesonide oral suspension)

Reference:

  1. EOHILIA (budesonide oral suspension) Prescribing Information. Takeda Pharmaceuticals, Inc.